Core Viewpoint - China Traditional Chinese Medicine (00570) anticipates a shift from profit to loss for the fiscal year ending December 31, 2025, with expected net losses ranging from RMB 350 million to 500 million, compared to a net profit of RMB 20.77 million in the same period last year [1] Group 1: Financial Performance - The adjusted net profit for the current period is expected to decline by 45% to 55%, with the previous year's figure at approximately RMB 635.5 million [1] - The board attributes the shift to losses primarily to the increased proportion of centralized procurement in the Chinese medicine formula granule business, intensified market competition, and a decrease in revenue scale and profitability [1] Group 2: Impairments and Adjustments - The current period is also impacted by increased goodwill impairment, intangible asset impairment, and credit impairment [1] - The adjusted net profit figure accounts for the effects of goodwill and related asset group impairments, as well as tax payments owed by certain subsidiaries [1]
中国中药发盈警 预计2025年度净亏损约3.5亿至5亿元